查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1557324

腦脊髓液 (CSF) 管理市場 – 2024 年至 2029 年預測

Cerebrospinal Fluid (CSF) Management Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 136 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球腦脊髓液（CSF）管理市場預計將從2024年的819,534,000美元擴大到2029年的1,036,706,000美元，複合年成長率為4.81%。

腦脊髓液 (CSF) 存在於大腦和脊髓中，為大腦提供機械和免疫保護。各種管理裝置，例如腦脊髓液引流系統和腦脊髓液分流器，控制腦脊髓液從身體心室的流動，並防止腦脊髓液不當積聚和水腦症。

新興國家多家神經科醫院的開拓以及對具有成本效益的治療的持續投資正在推動市場擴張。此外，神經系統疾病盛行率的增加、老年人口增加對微創手術的高需求、可支配收入的增加以及醫療基礎設施的進步也是促進腦脊髓液管理市場成長的因素之一。

此外，醫院正在透過引入新產品和技術改進來治療各種神經血管疾病，這可能會在整個預測期內提供良好的市場成長前景。根據美國美國神經病變的數據，全世界每 1000 名嬰兒中就有 1 到 2 名出生時患有水腦症。

全球業務的最大限制之一是合格的神經外科醫生的短缺，其數量不足以滿足快速成長的老年人口對優質醫療保健的需求。與腦脊髓液分流和感測器相關感染疾病相關的問題日益增多，預計將成為預測期內限制全球腦脊髓液管理市場成長的兩個主要問題。除此之外，設備的高成本和腦脊髓液分流引起的感染疾病阻礙了市場成長。

全球腦脊髓液 (CSF) 管理市場促進因素：

  • 神經和腦部疾病盛行率的增加預計將加速市場擴張。

腦脊髓液充當緩衝墊，保護大腦和脊髓免受突然損傷。它還可以去除大腦周圍不必要的成分，幫助中樞神經系統正常運作。腦脊髓液管理可防止滲漏影響大腦和脊髓。隨著腦損傷和神經病變的迅速增加，分流器和外部引流系統（EDS）等設備的需求預計也會增加。

根據世界神經病學聯合會 2023 年 10 月的新聞稿，神經系統疾病是全球第二大死亡和殘疾原因。根據該聯合會最近的一項研究，世界上近 40% 的人口患有某種形式的神經系統疾病。到 2050 年，這一數字預計將增加一倍，報告的病例主要發生在低收入和中等收入國家，目前這些國家佔全球神經系統死亡的 84%。

全球腦脊髓液（CSF）管理市場細分分析

  • 據估計，分流器佔了很大的市場。

依產品類型分類，全球腦脊髓液管理市場分為外部引流系統和分流器。由於世界各地進行的分流手術數量不斷增加，以及由於分流失敗或感染而導致的再次手術數量不斷增加，分流預計將在腦脊髓液管理行業中佔據主導地位。現代分流術的好處，例如減少再次手術的可能性和縮短平均住院時間，正在刺激該領域的擴張。

  • 兒科產品預計將佔據重要的市場佔有率。

按最終用戶分類，全球腦脊髓液 (CSF) 管理市場分為成人、兒童和老年。在預測期內，由於先天性水腦症的盛行率不斷增加以及兒科族群中進行的分流手術數量不斷增加，預計兒科類別將佔據重要的市場佔有率。

  • 在規定的時限內，醫院將佔據重要的市場佔有率。

全球腦脊髓液 (CSF) 管理市場按行業分析為醫院、診所等。由於人口老化中與腦脊髓液管理相關的住院病例數量較多，醫院部門佔據了很大的市場佔有率，預計在預測期內將以最快的速度擴張。

亞太地區預計將經歷顯著成長。

按地區分類，全球市場分為北美、南美、歐洲、中東和非洲以及亞太地區，其中亞太地區預計成長率最高。由於中國先天性水腦症盛行率上升以及各國老年人口不斷增加，亞太國家的醫療旅遊正在發展，推動了該地區市場的擴張。

此外，持續的研究合作和投資以加強神經系統疾病的治療預計也將推動該地區的市場擴張。例如，由生物技術部實施並由印度政府支持的失智症科學計劃，旨在研究老齡化人口中失智症的盛行率。

同樣，在研究機構加強神經系統疾病治療的策略性努力的推動下，北美預計將出現顯著成長。食品藥物管理局(FDA) 等主要機構正在核准針對老齡化人口的新神經病變治療方法，從而提供新的成長前景。此外，美敦力 (Medtronic)、強生 (Johnson &Johnson) 和 IntegraLifeSciences 等主要市場參與者的成熟存在也進一步推動了區域市場擴張。

全球腦脊髓液（CSF）管理主要市場開拓：

  • 2023年12月，Plus Therapeutic Inc.將與K2bio夥伴關係，為中樞神經系統癌症患者進行腦脊髓液癌症檢測和分子生物標記檢測。
  • 2023年6月，羅氏將推出“Elecsys(R) beta-澱粉樣蛋白(1-42) CSF II (Abeta42)”和“Elecsys(R) Total-Tau CSF檢測”，用於測量55歲及以上成年人類的阿茲海默症病理學已獲得 FDA 510(k) tTau 許可。
  • 2023 年 1 月，百健 (Biogen) 和 Arion Therapeutics 簽署了開發 ThecaFlex DRx (TM) 系統的許可和協議，該系統是一種植入式醫療設備，可對腦脊髓液進行ASO（反義寡核苷酸）治療。此次協議將最佳化百佳泰在腦脊髓液輸送技術的經驗，並改善神經系統疾病患者的治療體驗。

全球腦脊髓液（CSF）管理市場細分與分析如下：

依產品類型

  • 腦脊髓液分流術
  • 外部排水系統

按最終用戶

  • 兒科的
  • 成人用
  • 對於老年人

按行業分類

  • 醫院
  • 診所
  • 其他

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 其他中東/非洲
  • 沙烏地阿拉伯
  • 以色列
  • 其他
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 印尼
  • 泰國
  • 台灣
  • 其他

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球腦脊髓液（CSM）管理市場：依產品類型

  • 介紹
  • 腦脊髓液分流術
  • 外部排水系統

第6章全球腦脊髓液（CSM）管理市場：依最終使用者分類

  • 介紹
  • 小兒科
  • 成人用
  • 老年病

第7章全球腦脊髓液（CSM）管理市場：依產業分類

  • 介紹
  • 醫院
  • 診所
  • 其他

第8章全球腦脊髓液（CSM）管理市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Medtronic
  • Integra LifeSciences
  • Johnson & Johnson MEDTECH
  • B. Braun Melsungen AG
  • Spiegelberg GmbH & Co. KG（Acquired by SHS Medizintechnik Holding GmbH）
  • Sophysa（A subsidiary of tkb group）
  • Natus Medical Incorporated（Acquired by ArchiMed Group）
  • Argi Grup
  • Moller Medical GMBH
  • Delta Surgical
  • Wellong Instruments Co., Ltd.
簡介目錄
Product Code: KSI061611877

The global cerebrospinal fluid (CSF) management market is poised to expand from US$819.534 million in 2024 to US$1,036.706 million in 2029 at a 4.81% CAGR.

Cerebrospinal fluid (CSF) is found in the brain and spinal cord that protects the brain mechanically and immunologically. Various management devices, such as CSF drainage systems and CSF shunts, control the flow of CSF away from the ventricles in the body, preventing inappropriate CSF accumulation and hydrocephalus.

Developing several neuro-hospitals in emerging countries and ongoing investments for cost-effective treatment drive market expansion. Furthermore, the growing prevalence of neurological disorders, the high demand for minimally invasive surgeries fuelled by the growing geriatric population, rising disposable incomes, and advancing healthcare infrastructure are among the other contributing factors to the cerebrospinal fluid management market growth.

Moreover, hospitals are treating various neurovascular illnesses due to introducing new products and technical improvements that will give lucrative market growth prospects throughout the projected period. According to the National Institute of Neurological Disorders and Stroke, one to two out of every 1000 babies worldwide are born with hydrocephalus.

One of the most significant constraints on global business is the scarcity of qualified neurosurgeons, whose existing number is insufficient to meet the demand for quality healthcare in a rapidly rising senior population. Rising problems connected with CSF shunts and sensor-related infections are two major issues predicted to limit the worldwide cerebrospinal fluid management market's growth in the projected period. Apart from that, the market's growth is hampered by the high cost of devices and the infections generated by CSF shunts.

Global Cerebrospinal Fluid (CSF) Management Market Drivers:

  • The growing prevalence of neurological & brain disease is expected to accelerate the market expansion.

The cerebrospinal fluid protects the brain and spinal cord from sudden injury by acting as a cushion. It also removes unnecessary elements surrounding the brain, assisting in the proper functioning of the central nervous system. CSF management prevents any leaks that might affect the brain or spinal cord. With the booming strength of brain injuries and neurological disorders, the demand for devices such as shunts and external drainage systems (EDS) is also anticipated to increase.

According to the October 2023 press release of the World Federation of Neurology, neurological disorders account for the second highest causes of death and disability globally. As per the federation's recent study, nearly 40% of the global population suffers from some neurological condition; by 2050, the projected number will double, with major cases being reported in low to middle-income countries, which currently account for 84% of all neurological deaths occurring globally.

Global Cerebrospinal Fluid (CSF) Management Market Segment Analysis

  • Shunts are estimated to account for a considerable share of the market.

By product type, the global cerebrospinal fluid management market is segmented into external drainage systems and shunts. Shunts are expected to dominate the CSF management industry owing to the rising number of shunting procedures conducted worldwide and the increasing number of revision shunt surgeries due to their malfunction and infection. The advantages of modern shunts, such as the reduced likelihood of revision surgery and a shorter average hospital stay, fuel the segment's expansion.

  • Pediatric is projected to account for a considerable market share.

By end-users, the global cerebrospinal fluid (CSF) management market is divided into adult, pediatric, and geriatric. During the forecast period, the paediatric category is estimated to account for a considerable market share fuelled by the increased prevalence of congenital hydrocephalus and the increasing number of shunting procedures performed in the paediatric population.

  • Hospitals will account for a remarkable market share during the given timeframe.

The global cerebrospinal fluid (CSF) management market is analyzed by industry into hospitals, clinics, and others. Due to the large number of hospital cases linked to CSF management in the aging population, the hospital segment is anticipated to account for a sizable market share and expand at the quickest rate over the projection period.

Asia Pacific is poised for significant growth.

By geography, the global cerebrospinal fluid (CSF) management market is segmented into North America, South America, Europe, the Middle East and Africa, and Asia Pacific, where the latter is expected to grow at the highest rate. The developing medical tourism in Asia Pacific countries, fuelled by the rising prevalence of congenital hydrocephalus in China and the growing geriatric population in various nations, are driving regional market expansion.

Moreover, the ongoing research collaboration and investment to bolster treatment for neurological disorders are also expected to drive the regional market expansion. For instance, the "Dementia Science Program" implemented by the Department of Biotechnology and backed up by the Indian government aimed to study the prevalence rate of dementia in the aging population.

Likewise, North America is expected to grow considerably, fuelled by the strategic efforts undertaken by research institutes to bolster the treatment of neurological conditions. Major organizations, namely the Food and Drug Administration, are approving new neuropathy treatments for aging populations, which has provided new growth prospects. Additionally, the well-established presence of major market players, namely Medtronic, Johnson & Johnson, and IntegraLifeSciences, is acting as additional driving factors for regional market expansion.

Global Cerebrospinal Fluid (CSF) Management Key Market Development:

  • In December 2023, Plus Therapeutic Inc. formed a partnership with K2bio to implement CSF cancer and molecular biomarker testing for CNS cancer patients. The respective processing & testing partnership forms part of Plus Therapeutics' strategy to address the therapeutic and diagnostics needs of CAN patients.
  • In June 2023, Roche received the FDA's 510(k) clearance for its "Elecsys(R) beta-Amyloid (1-42) CSF II (Abeta42)" and "Elecsys(R) Total-Tau CSF assays (tTau)" which would measure Alzhamier's pathology in adults aged 55 years and above. The clearance further adds to Roche's portfolio for defining the pathological process for Alzheimer's amyloid plaques, neurodegeneration, and tau tangles.
  • In January 2023, Biogen Inc. formed a license and collaboration agreement with Alyone Therapeutics for the development of the latter's "ThecaFlex DRx(TM) System" into an implantable medical device that would deliver ASO (Antisense Oligonucleotide) therapies to cerebrospinal fluid. The agreement will optimize Alyone's experience in CSF delivering technology, thereby improving the treatment experience for patients suffering from neurological conditions.

The Global Cerebrospinal Fluid (CSF) Management market is segmented and analyzed as follows:

By Product Type

  • CSF Shunts
  • External Drainage System

By End User

  • Pediatric
  • Adult
  • Geriatric

By Industry

  • Hospital
  • Clinics
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL CEREBROSPINAL FLUID (CSM) MANAGEMENT MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. CSF Shunts
  • 5.3. External Drainage System

6. GLOBAL CEREBROSPINAL FLUID (CSM) MANAGEMENT MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Pediatric
  • 6.3. Adult
  • 6.4. Geriatric

7. GLOBAL CEREBROSPINAL FLUID (CSM) MANAGEMENT MARKET BY INDUSTRY

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Others

8. GLOBAL CEREBROSPINAL FLUID (CSM) MANAGEMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. Israel
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Medtronic
  • 10.2. Integra LifeSciences
  • 10.3. Johnson & Johnson MEDTECH
  • 10.4. B. Braun Melsungen AG
  • 10.5. Spiegelberg GmbH & Co. KG (Acquired by SHS Medizintechnik Holding GmbH)
  • 10.6. Sophysa (A subsidiary of tkb group)
  • 10.7. Natus Medical Incorporated (Acquired by ArchiMed Group)
  • 10.8. Argi Grup
  • 10.9. Moller Medical GMBH
  • 10.10. Delta Surgical
  • 10.11. Wellong Instruments Co., Ltd.